Trial Profile

Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribociclib (Primary) ; Enzalutamide
Indications Prostate cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Apr 2026 Treatment arms changed from 1 to 5, patient number changed from 46 to 52, treatment allocation changed to randomized.
22 Apr 2026 Status changed to discontinued.
22 Apr 2026 Actual primary completion date changed from 6 Dec 2022 to 7 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com